Kiniksa Pharmaceuticals International, plc
KNSA
주식 순위
#2868
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
주가
$83.13
마지막 동기화: 2026-10-20
시가총액
$6.49B
변동 (1일)
4.59%
변동 (1년)
113.97%
국가
GB
거래 Kiniksa Pharmaceuticals International, plc (KNSA)
카테고리
Healthcare
Kiniksa Pharmaceuticals International, plc (KNSA)의 매출
Jun 2026 기준 매출 TTM: $840.85M
Kiniksa Pharmaceuticals International, plc의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $840.85M입니다. 2023년에 회사는 $270.26M의 수익을 올렸으며 이는 2022년의 $220.18M 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Kiniksa Pharmaceuticals International, plc의 수익 기록 (2016 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $840.85M | 98.67% |
| 2024 | $423.24M | 56.60% |
| 2023 | $270.26M | 22.74% |
| 2022 | $220.18M | 471.24% |
| 2021 | $38.54M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $2.54B | 201.60% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $830.81M | -1.19% |
US
|
